GENE ONLINE|News &
Opinion
Blog

Blood Cancer
Trending SkysonaCALD
FDA Investigates Reports of Blood Cancer Cases Linked to Gene Therapy
2024-12-02
Trials & Approvals Allogeneic Cell TherapyFDA Approval
Gamida’s Allogeneic Cell Therapy Snags FDA Approval for Blood Cancers
2023-04-18
Licensing Kite Pharma
Kite to Use Refuge’s Gene Expression Platform for New CAR-T Therapies
2022-10-21
Licensing Oncology
ADC Therapeutics and Sobi Sign $435 Million Deal to Expand Blood Cancer Drug’s Market
2022-07-11
Funding Series B Funding
Dren Bio Draws $65 Million, Aiming for Phase 1 of ADCC Lead
2022-06-15
Trials & Approvals Follicular Lymphoma
Europe Okays Roche’s CAR-T Competitor for Blood Cancer
2022-06-09
Asia-Pacific Cell Therapy
AbClon, HK inno.N Collaborates to Take On Novartis’ CAR T-Cell Therapy
2022-02-15
Trials & Approvals
Cartesian’s Off-the-shelf RNA Therapy for Myeloma Enters Clinical Trials
2022-01-27
China Multiple MyelomaChina NMPA
Antengene’s XPO1 Inhibitor Receives First-In-Class Approval in China for Multiple Myeloma
2021-12-20
Feature Blood CancerCancer Immunotherapy
ASH 2021: 4 Immunotherapies Highlight Transformations in Blood Cancer Treatment
2021-12-13
Trials & Approvals Blood Cancer
FDA Approves First Interferon Therapy for Rare Blood Cancer
2021-11-15
M&A
Servier Aims to Expand Portfolio for Hematological Cancers by Acquiring Agios
2020-12-23
Trials & Approvals CD38
Spotlight: Cancer Drug Licensed from Danish Antibody Developer Continues to Reap Benefits for Janssen
2020-09-04
Trials & Approvals Multiple Myeloma
GSK’s anti-BCMA Therapy Notches FDA Approval for Refractory Multiple Myeloma
2020-08-09
Korean Biotech, AbClon Enters Trials with New CAR-T Molecule against Ovarian Cancer
2020-04-23
1 2
LATEST
How FIRM is Shaping Regenerative Medicine in Japan
2024-12-09
AI, Smart Tech, and ICT to Unite the Global Biotech and Healthcare Industries in 2025
2024-12-06
Core8 Group to Establish Vietnam’s First Comprehensive Biotechnology Incubator
2024-12-05
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
2024-12-05
Ipsen Bets $600M on Biomunex’s First-in-Class T-Cell Engager BMX-502
2024-12-03
Gilead Strikes Again: $415M Bet on ADCs with Tubulis Deal
2024-12-03
From Europe to the Middle East: AMS BioteQ Expands Its Global Reach, Setting New Milestones in Medical Innovation
2024-12-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top